ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting

Matthew A. Gubens, MD, MS, FASCO, highlights the importance of identifying genetic targets in metastatic non–small cell lung cancer (NSCLC), emphasizing the latest updates and strategies.

The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.

Quadruple therapies including immunotherapy agents show promise in treating patients with multiple myeloma.

Gender disparities among oncology health care professionals have significant consequences for both the physicians and the patients they treat.

Pharmacists also have the resources to help advocate for better care for patients.

Early safety studies of NK-cell infusion have demonstrated the potential of NK-cell infusion, showing it may be the next revolution in cancer treatment.

There are currently no effective treatments for CIPN prevention.

These data support a paradigm shift in the treatment of locally advanced rectal cancer.

With approximately 2 years of additional follow-up, lenvatinib plus pembrolizumab maintained robust effectiveness for nearly every patient.

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

Updated phase 3 trial data provide practice-changing findings.

These study results may inform clinical practice strategies this year and beyond.

Approximately 50% of patients with refractory or relapsed disease achieved complete response following treatment with the Janus kinase 1 (JAK1) inhibitor.

Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.

Earlier in June, Govindan led an educational session about genomic testing at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

The folate alpha receptor (FRα) does have a toxicity profile, but unlike other chemotherapies, it does not severely compromise bone marrow and may improve ability to receive more therapies.

Expert provides numerous resources to learn more about the Centers for Medicare & Medicaid Services Enhancing Oncology Model.

Additionally, data from the SCARLET trial presented at ASCO 2023 indicate the safety and efficacy of sotorasib in combination with platinum-based chemotherapy treating non¬–small cell lung cancer.

The combination also reduced the risk of developing distant metastasis or death by 65% in patients with high-risk stage 3/4 melanoma.

Trial results support 5.4 mg/kg of trastuzumab deruxtecan as the optimal dose in individuals with HER2+ metastatic colorectal cancer.

Until this study, adjuvant immunotherapy was standard of care for stage 3B melanoma but not stage 2, which has relatively similar survival rates and risk of recurrence.

Asking patients to “give us a month of [their] life” for autologous chimeric antigen receptor therapy may reduce relapse or recurrence for 4 years or more, according to expert.

Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.

Nivolumab plus ipilimumab combination improved overall survival, with 21% of individuals with metastatic non–small cell lung cancer treated with the combination and 2 cycles of chemotherapy alive compared to 16% with chemotherapy alone.

Positive findings in patients with advanced high-grade epithelial ovarian cancer were presented during an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

Expert suggests that mirvetuximab soravtansine-gynx, which received accelerated approval in the platinum-resistant ovarian cancer setting in 2022, is the most promising agent in more than a decade that targets folate receptor alpha.

Current standard of care gives 2 poor options to patients, neither of which cure grade 2 gliomas.

When physicians followed up, rates of screening improved for breast and cervical cancer by 50% and 250%, respectively, among eligible cancer survivors.